Drug Trial Radar · NCT05507450
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,271
Actual
Start
Sep 7, 2022
Primary completion
Jun 5, 2023
Study completion May 7, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid-Potency Level vaccine. This study will also evaluate the safety and tolerability of 3 different V181 potency level vaccines. The primary hypothesis of the study is that the V181 Low-Potency Level vaccine is non-inferior to the V181 Mid-Potency Level vaccine for each of the 4 dengue serotypes based on GMTs at Day 28 post-vaccination.
Conditions
- Dengue Disease
- Dengue Virus
Interventions
V181 High-Potency LevelBiological
0.5 mL SC dose of V181 High-Potency vaccine
V181 Mid-Potency LevelBiological
0.5 mL SC dose of V181 Mid-Potency vaccine
V181 Low-Potency LevelBiological
0.5 mL SC dose of V181 Low-Potency vaccine
PlaceboBiological
0.5 mL SC dose of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)Time frame: Day 28 post-vaccination
- Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)Time frame: Up to 28 days post-vaccination
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
California Research Foundation ( Site 0114)
San Diego, California
Advanced Medical Research Institute ( Site 0115)
Miami, Florida
Rochester Clinical Research, Inc. ( Site 0122)
Rochester, New York
University of Texas Medical Branch ( Site 0113)
Galveston, Texas
IMA Clinical Research San Antonio ( Site 0111)
San Antonio, Texas
Alliance for Multispecialty Research LLC (AMR - Norfolk) ( Site 0123)
Norfolk, Virginia
Paratus Clinical Research Western Sydney ( Site 0007)
Blacktown, New South Wales, Australia
Emeritus Research ( Site 0010)
Botany, New South Wales, Australia
USC Clinical Trials Moreton Bay ( Site 0001)
Morayfield, Queensland, Australia
USC Clinical Trials Sunshine Coast ( Site 0005)
Sippy Downs, Queensland, Australia
USC Clinical Trials Brisbane (South Bank) ( Site 0006)
South Brisbane, Queensland, Australia
Emeritus Research ( Site 0009)
Camberwell, Victoria, Australia
Diex Recherche Quebec Inc. ( Site 0022)
Québec, Quebec, Canada
Diex Recherche Joliette ( Site 0023)
Saint-Charles-Borromée, Quebec, Canada
Diex Recherche Sherbrooke Inc. ( Site 0024)
Sherbrooke, Quebec, Canada
Diex Recherche Victoriavile Inc. ( Site 0021)
Victoriaville, Quebec, Canada
FVR, Kokkolan rokotetutkimusklinikka ( Site 0037)
Kokkola, Keski-Pohjanmaa, Finland
FVR, Oulun rokotetutkimusklinikka ( Site 0032)
Oulu, North Ostrobothnia, Finland
FVR, Tampereen rokotetutkimusklinikka ( Site 0039)
Tampere, Pirkanmaa, Finland
FVR, Porin rokotetutkimusklinikka ( Site 0033)
Pori, Satakunta, Finland
FVR, Seinäjoen rokotetutkimusklinikka ( Site 0040)
Seinäjoki, South Ostrobothnia, Finland
FVR, Turun rokotetutkimusklinikka ( Site 0031)
Turku, Southwest Finland, Finland
FVR, Espoon rokotetutkimusklinikka ( Site 0036)
Espoo, Uusimaa, Finland
FVR, Etelä-Helsingin rokotetutkimusklinikka ( Site 0038)
Helsinki, Uusimaa, Finland
FVR, Itä-Helsingin rokotetutkimusklinikka ( Site 0035)
Helsinki, Uusimaa, Finland
Berliner Centrum für Reise- und Tropenmedizin ( Site 0043)
Berlin, Germany
Bernhard Nocht Institute for Tropical Medicine ( Site 0041)
Hamburg, Germany
Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Division of Infectious Diseases and Tropical (
München, Bavaria, Germany
Rambam Health Care Campus-Oncology ( Site 0053)
Haifa, Israel
Hadassah Medical Center-Clinical Reaserch Unit ( Site 0052)
Jerusalem, Israel
Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0051)
Ramat Gan, Israel
Kaohsiung Medical University Hospital-Infectious diseases Division, Department of Internal Medicine
Kaohsiung City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.